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Abstract
Introduction: Haemostasis after liver resection may be difficult to achieve as a result of the presence of
challenging bleeding, the anatomic landscape of the liver and the quality of tissue making up the hepatic
parenchyma. The fibrin pad (FP) is a topical absorbable haemostat designed to be effective in a variety
of tissues and across multiple bleeding intensities. This is the first clinical trial to evaluate the hemostat's
safety and effectiveness in controlling bleeding during elective hepatic resection.
Methods: This prospective, randomized, controlled superiority trial enrolled 104 subjects undergoing
elective hepatectomy in 5 countries. After parenchymal transection, subjects with an appropriately
defined target bleeding site (TBS) were stratified according to the type of hepatic parenchyma and
immediately randomized 1:1: FP versus Standard of Care (SoC). SoC comprised manual compression
with the use of an approved topical absorbable haemostat. The primary endpoint was haemostasis at
4 min from identification of the TBS, with no re-bleeding requiring re-treatment prior to abdominal closure.
Results were stratified for both normal and abnormal (steatosis or cirrhosis) hepatic parenchyma. All
subjects were followed for 60 days post-operatively.
Results: The intent-to-treat (ITT) analysis showed an overall treatment difference of 53.0% (P < 0.001),
82.5% (33/40 FP) versus 29.5% (13/44 SoC) in achieving haemostasis at 4 min with no re-bleeding
requiring treatment up to wound closure. The per protocol analysis showed an overall treatment difference
of 65.7% (P < 0.001), with 33/35 successes (94.3%) in the FP group and 12/42 in the SoC group (28.6%).
The stratification results showed treatment differences between the normal parenchyma group, 63.6%
(95.8% FP versus 32.3% SoC P < 0.001) and a larger difference of 72.7% in the abnormal parenchyma
group (90.9% FP versus 18.2% SoC P = 0.0003). Post-operative intra-abdominal fluid collections were
less frequent in the FP group (3.4% FP versus 13.3% SoC P = 0.059). There was no difference in the
safety profile between the FP or SoC groups.
Conclusions: The FP is safe and effective when used as an adjunct to achieve haemostasis during
hepatic surgery. The success rate of achieving haemostasis with a FP remained high compared with the
SOC group, especially in steatotic or cirrhotic liver tissue where the control success rates diminish. In
addition, FP treatment of hepatic parenchymal surfaces may reduce the risk of post-operative biliary and
fluid collections.
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Introduction
Bleeding during surgery can be focal, regional or generalized.
Focal bleeding usually comes from an open vessel and can be
addressed with either suture ligation or, if minor, thermal means
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such as diathermy. Generalized bleeding usually reflects a systemic
issue with coagulation and requires the administration of blood
and blood products as well as specific coagulation factors.
Regional bleeding is often more difficult to control as it arises
from a specific area, often a tumour bed or parenchymal surface.
Focal techniques can be used as well as widespread application of
thermal energy with diathermy or argon beam coagulation or the
application of surgical packs.
The liver can represent a particular challenge in terms of
regional bleeding. Once the hepatic parenchyma has been divided
during a liver resection a bare parenchymal surface is left. Bleeding
can arise from this and may be exacerbated by high venous pres-
sures, intermittent in flow occlusion causing periods of relative
ischaemia1–3 and fragile parenchyma which may tolerate suture
application poorly. Analysis of the causes of blood loss during a
hepatectomy shows that significant bleeding can occur from the
parenchymal surfaces during the split rather than from control of
the major inflow or outflow structures.1 Furthermore, blood loss
can be significantly greater in patients with abnormal parenchyma
as a result of cirrhosis or steatosis a undergoing hepatectomy
emphasizing the advantage of a normal parenchyma in managing
a haemorrhage by conventional means.4 In addition, there is
increasing evidence that transfusion of blood or blood-derived
products can be associated with significant morbidity. Conse-
quently, there is increased focus on reducing blood loss and elimi-
nating transfusion requirements in all forms of hepatic surgery.3
The fibrin pad (FP) is a novel means of treating regional bleed-
ing during surgical procedures. The FP is made up of a flexible
matrix of polyglactin 910 filaments needle punched into one side
of a backing of oxidized regenerative cellulose 10.2 cm square.
Human thrombin and human fibrinogen are then bound to the
polyglactin filaments (Fig. 1). The FP has a biological side with an
enhanced surface area as a result of the presence of multiple
polyglactin filaments with bound thrombin and fibrinogen. The
other side is non-biological and consists only of oxidized regen-
erative cellulose. The FP works by applying the biological side to
an area of active bleeding. Activation of thrombin and fibrinogen
results in the development of a local clot and adherence of the FP
to the surface. The FP is absorbable and remains in situ at the end
of the surgical procedure. The FP has been assessed in two previ-
ous randomized trials of moderate (Clinicaltrials.gov identifier:
NCT00658723) and severe soft tissue bleeding (Clinicaltrials.gov
identifier: 00977925) and has been shown to be safe and effective
in these clinical settings.5,6
This investigation was designed to assess the effectiveness of the
FP at controlling parenchymal edge bleeding after an elective
hepatectomy. This trial was also designed to define the ability of
the FP to achieve haemostasis in both normal and cirrhotic or
steatotic livers after hepatectomy, to assess the safety of the FP in
this setting.
Materials and methods
This was a randomized, controlled superiority study evaluating
the effectiveness of the FP compared with standard of care (SoC)
methods utilized to control bleeding in hepatic parenchyma
after an elective liver resection (Clinialtrials.gov identifier:
NCT01166243). The trial was carried out in 10 centres in Europe,
United Kingdom, Australia and New Zealand (see Acknowledge-
ments) supervised by an investigator in each centre. The trial
was designed to align with the CONSORT guidelines and to be
reported in a manner consistent with the CONSORT statement.7
Patients
Patients undergoing a partial hepatectomy were recruited for the
trial by the investigators and local trial coordinators. Patients were
Haemostatic
matrix
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Non-biological side
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Figure 1 The fibrin pad non-biological side (left), biological side (middle) and graphic demonstrating trilayer composition (right)
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considered eligible for enrolment if they were older than 18 years
of age and required urgent or elective hepatic resection and were
able to provide written, informed consent. Patients were excluded
from enrolment if admitted for trauma surgery, undergoing a liver
transplant for fulminant hepatic failure, had active sepsis around
the liver, a known tolerance to blood products or one of the
components of the FP, were unwilling to receive blood products,
were a known and current alcohol or drug abuser, were pregnant
or breast feeding, or had participated in another investigational
drug or device research study within the previous 30 days.
Potentially eligible patients were reviewed in outpatient clinics
and the trial discussed. Patients were enrolled after the consent
process and then were screened (Table 1). This involved a full
history, physical examination, determination of a full blood
count, liver function tests, coagulation studies and, if appropriate,
a pregnancy test. A total of 5 ml of blood was also stored at -80°C,
with the patient’s specific consent, for up to 5 years for later
determination of viral titres if required. Screening occurred
within 21 days of the surgical procedure. The patient’s throm-
boembolism risk was also assessed using the system of Caprini.8
Further review of potential exclusion criteria and medications was
undertaken on admission for a hepatectomy (baseline, Table 1).
Study procedure
Potentially eligible patients were admitted under the operating
surgeon. The surgical procedure including hepatic mobilization,
vascular control, parenchymal division and use of post-operative
surgical drains was performed according to the surgeon’s standard
practice. Both the FP and any other absorbable haemostatic prod-
ucts that constituted routine standard of care (such as oxidized
regenerative cellulose) were prepared9 and available in the sterile
field on the instrument trolley. Patient randomization occurred
after the resection if the surgeon encountered an appropriate
target bleeding site in the hepatic parenchyma. The target bleeding
site (TBS) was defined as a bleeding site that, after 30 s of firm
manual compression, had persistent bleeding that required imme-
diate attention and where conventional methods of control
(suture, ligation or cautery) were felt to be ineffective, impractical
or inappropriate. At this point randomization occurred by
opening the appropriate randomization envelope and a stopwatch
started simultaneously.
Subjects randomized to SoC received continuous manual pres-
sure with a gauze and oxidized regenerative cellulose for a total of
4 min after randomization. Subjects randomized to FP were
treated with a FP over the TBS and continuous firm manual
Table 1 Schedule of study events
Procedure Screening Baseline Surgical
procedure
Post-surgery to
discharge
Day 1 and
3,4 or 5
30-day
follow-up
60-dayd
Inclusion/exclusion X X X
Informed consent X
Demographics X
Medical history X
Concomitant medications X X X X X X
Physical exam X X X
Complete blood counta X X X
Liver function testsb X X X X
Coagulation studiesc X X X
Haemoglobin, Hct only X X X X
Pregnancy test (if applicable) X
Viral safety X
Randomization X
Treatment application X
Intra-operative details X
Determination of haemostasis X
Bleeding & thrombotic complications X X X X
Adverse events X X X X
Operative/surgical information X X
aAll complete blood counts included are differential.
bLiver function tests included serum bilirubin, aspartate transaminase (AST), gamma glutamyl transferase (gGT), total protein and albumin
concentrations.
cCoagulation studies included prothrombin time (PT), partial thromboplastin time (PPT), international normalized ratio (INR), platelet count and
fibrinogen determinations.
d60-day follow-up could be conducted via a telephone interview.
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compression which was released 4 min after randomization. The
total period of manual compression was somewhat less than
4 min taking into account the time required for randomization
and the transfer of the SoC or FP from the theatre instrument
table to the surgeon and its application. Haemostasis was assessed
at 4 min from randomization, at 10 min from randomization and
at the completion of surgery immediately prior to fascial closure.
Prior to randomization, the site and nature of the primary
operative procedure was recorded as well as the type of hepatic
parenchyma (normal, cirrhotic or steatotic). The area of the TBS
and whether it was arterial, venous or mixed and pulsatile or
non-pulsatile was noted after randomization. The area of the
transected hepatic parenchyma was measured directly with a
small, sterile hand ruler.
Application of the fibrin pad and standardized
surgeon training
The FP has a biological side in which the surface area has been
increased by the application of multiple polyglactin filaments.
Human thrombin and fibrinogen are bound to these filaments.
The pad functions by careful application of the biological side to
the bleeding surface. The FP can be only handled by the non-
biological side and any moisture applied to the FP will result in
early activation of thrombin and fibrinogen and a loss of its effi-
cacy. In addition, the FP must be closely applied to the surface so
that it conforms to the tissue. The FP must be closely approxi-
mated to tissues and wrinkles should be avoided during applica-
tion to maximize effectiveness. Consequently, while the FP is
straightforward to use, some training and understanding of its
composition and mechanism of action are necessary.
Prior to the trial commencement, all surgeons and trial coor-
dinators involved in this investigation attended full-day teaching
sessions on the use of the FP and an opportunity was given to use
the FP under careful supervision on a number of biological
models of bleeding in various sites. In this way the application
technique of investigators was standardized as well as clearly
defining the size and severity of the TBS required for patient
randomization. Teaching videos of example TBS and correct
application of the FP were also available. In addition, the study
included a ‘run in’ phase in which the first two eligible subjects for
each participating investigator surgeon without prior experience
of the FP was not randomized and had their target bleeding sites
treated with the FP.
Definition of target bleeding site
The TBS was defined as a bleeding site that, after 30 s of firm
manual compression, had persistent bleeding that required imme-
diate attention and where conventional methods of control
(suture, ligation or cautery) were felt to be ineffective, impractical
or inappropriate. The TBS was also required to be a size that could
be adequately covered by a single 10.2 cm by 10.2 cm FP. Bleeding
from large arteries or veins where, the injured vascular wall
required repair with the maintenance of vessel patency, was
excluded. The FP was not used in place of sutures or other forms
of mechanical ligation for the treatment of major arterial bleed-
ing. In this investigation, the aim was to use the FP in the clinical
setting where bleeding occurs from the parenchymal surface after
a partial hepatectomy. In this setting, heat-based methods of
coagulation are often inadequate and the surface is fragile and
may not tolerate the application of sutures.
Definition of post-operative bile leak
A bile leak was defined as the presence of bile containing fluid in
a drain. The bilirubin concentration in the fluid was required to be
at least three times higher than the upper normal serum levels in
patients with a normal post-operative serum bilirubin or a 50%
higher bilirubin level in fluid than serum in patients with post-
operatively elevated serum bilirubin levels.
Management of protocol violations
All protocol deviations were recorded and classified as major (one
that may have an impact on the randomization assignment or an
impact on the primary endpoint) or minor. All protocol devia-
tions were reviewed by medically qualified monitoring personnel
and the study team prior to database lock. All subjects were ana-
lysed on an intention-to-treat (ITT) basis.
Safety and monitoring
The protocol, consent and patient information documents were
submitted by each investigator to the appropriate independent
Ethics Committee or Institutional Review Board. Approval from
these organizations was obtained and documented prior to any
study-related procedure being undertaken. The study was con-
ducted in accordance with the International Conference on Har-
monization (ICH) Harmonized Tripartite Guideline for Good
Clinical Practice (1996),10 the US Food and Drug Administration
(FDA) regulations (Title 21 Code of Federal Regulations [CFR]
Parts 50, 54, 56 and 312),11 the Declaration of Helsinki (2008),12
the European Union Trial Directive (2011/20/EC, May 2001) and
the EU GCP Directive (2005/28/EC).13
An independent Data Safety Monitoring Board (DSMB) was
established and reviewed all data for any potential safety issues for
the duration of the study. A Clinical Events Committee (CEC) was
also created to adjudicate adverse events that were potentially
related to the TBS bleeding or thrombotic events. Membership of
these boards was independent with no affiliation to the trial
sponsor.
All adverse events were recorded and reviewed by the DSMB.
Serious adverse events were defined as adverse events that poten-
tially prolonged the duration of hospital stay.
Statistical methods
The trial reporting and analysis were aligned with the CONSORT
check list. The sample size was determined based on previous
clinical trials utilizing the FP in severe soft tissue bleeding and
assumed that the FP performance would be no worse than 75%
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with at least a 25% treatment difference with standard of care.14
Random allocation of patients to the FP or SoC groups was gen-
erated by a computer program and validated by a secondary stat-
istician. The allocation was on sequentially numbered concealed
envelopes.
Three analysis sets were defined. ITT set consisted of all rand-
omized subjects. Subjects who did not complete the procedure
after randomization were considered failures and included in the
ITT analysis. An evaluable set (or per protocol; PP) consisted of all
ITT subjects who had no major protocol deviations, and a safety
set consisted of all subjects who received treatment (the ITT set
plus the ‘run in’ phase patients). Patients were randomized to FP
or to SoC with a 1:1 allocation ratio. The sample size required was
not fixed but was dependent on the data with the first planned
interim data analysis at 80 patients in the ITT group. This was the
only analysis performed and the trial was stopped at this point.
The Whitehead triangular test15 for a binary response variable
was utilized (PEST 4.4 software; Department of Mathematics and
Statistics, University of Lancaster, Lancaster, UK) for primary
response variables with a two-sided alpha of 0.05 and power 0.9.
The assumed success rate in the control arm was 50% and in the
FP arm was 75%. Direct comparison of secondary effectiveness
variables between the treatment and control group was under-
taken using Wilcoxon’s Rank-Sum test and 95% confidence limits
were calculated using a distribution-free approach (SAS, Version
9.2; SAS Institute Inc., Cary, NC, USA).
Results
Patients
One hundred and four patients were included in the trial. Twenty
non-randomized subjects were treated with the FP during the
run-in phase of the study. The safety set consisted of all rand-
omized patients as well as the 20 patients treated with FP during
the ‘run in’ phase and comprised 59 patients treated with FP and
45 patients treated with SoC. This ‘run in’ phase was incorporated
to allow surgeons familiarity with the FP under operative condi-
tions. The ITT set, defined as all randomized patients only, con-
sisted of 40 patients treated with FP and 44 patients treated with
SoC (Fig. 2). One subject was randomized to FP but received SoC
and this subject was analysed in the FP group for the ITT set and
the SoC group for the safety set. Analysis of efficacy data was
performed on both the ITT and safety set whereas safety variable
analysis was carried out on the safety set. Patient demographics
for the ITT set are summarized in Table 2, whereas patient diag-
noses, operative procedures and parenchymal characteristics are
summarized in Table 3.
Surgical drains were placed at the end of the procedure in 44/59
(74.6%, median 1 drain, range 1–3 drains) of patients treated with
the FP and 36/45 (80%, median 1 drain, range 1–6 drains) of
patients treated with SoC.
Classification of TBS
The characteristics of the TBS are summarized in Table 4.
Treatment efficacy
The primary efficacy endpoint was the proportion of patients
achieving haemostasis (defined as no detectable bleeding) at the
TBS 4 min after randomization with no re-bleeding requiring
treatment at the TBS at any time prior to wound closure. At 4 min
after randomization with the release of manual compression,
34/40 patients (85%) in the FP achieved haemostasis compared
Total subjects
n = 104
Randomized subjects
n = 84
Non-randomized 
(‘run-in’) subjects
n = 20
Standard of care
n = 45*
Fibrin pad
n = 39*
Figure 2 Disposition of study subjects by treatment (safety set).
*One subject was randomized to the fibrin pad (FP) but received
standard of care (SoC) and this subject is analysed in the FP group
for the intention-to-treat (ITT) set and the SoC group for the safety
set
Table 2 Demographic details of patients in the intention-to-treat (ITT)
set
Category Fibrin pad
(n = 40)
Standard of
care (n = 44)
Median age (range) 65 (31–82) 65.5 (39–82)
18–49 years 6 7
50–64 years 12 14
65–74 years 13 13
75 years 9 10
Gender
Male 24 24
Female 16 20
Median body mass index
kg/m2 (range)
27 (15–41) 25 (18–43)
Underweight 1 1
Normal 13 15
Overweight 12 17
Obese 13 9
Morbidly obese 1 1
Smoking history
Yes 24 22
No 16 22
Venous thrombosis risk score8 14.7  2.6 14.3  2.4
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with 17/44 (38.6%) in the SoC group. The number of subjects
with haemostasis at 4 min and requiring no treatment for rebleed-
ing was 33/40 (82.5%) in the FP group and 13/44 (29.5%) in the
SoC group (P < 0.0001) if missing data are imputed as failures in
both treatment groups (Table 5). The efficacy of the FP was com-
parable in both normal and abnormal parenchymal groups
although SoC was less effective in patients with abnormal paren-
chyma (Table 5). In the ITT set, seven patients treated with FP
were considered treatment failures and all were included in the
ITT analysis. In one patient bleeding was present at 4 min but not
at 10-min compression. One patient was wrongly randomized to
SoC because the wrong randomization envelope was opened. This
patient was treated with SoC but included in the FP group for ITT
analysis. One subject developed further bleeding from the TBS
after the FP was dislodged at 9 min having achieved haemostasis
at 4 min and this was the only patient treated with FP classified as
rebleeding. One patient had an arterial bleeding point inappro-
priately treated with FP. This TBS was an exclusion criterion.
Table 3 Diagnoses, operative procedures and parenchymal type for the safety set
Category Fibrin pad (n = 59) Standard of care (n = 45)
Diagnosis
Metastatic colorectal cancer 44 34
Hepatocellular carcinoma 8 7
Cholangiocarcinoma 1 3
Haemangioma 2 1
Other 4 0
Duration of surgery (mean: range) 191 min (60–584) 184.4 min (75–397)
Operative procedures
Anatomic 38 31
Right hepatectomy 18 15
Left hepatectomy 6 5
Left lateral sectionectomy 5 4
Segmentectomy 3 3
Extended right hepatectomy 4 1
Extended left hepatectomy 0 1
Posterior right sectionectomy 1 2
Subsegmental resection 1 1
Non-anatomic 17 9
Other 4 5
Hepatic parenchyma
Normal 41 33
Abnormal 18 12
Cirrhotic 3 5
Steatotic 13 3
Other 2 4
Table 4 Summary of the characteristics of the target bleeding site (TBS) for the fibrin pad (FP) and standard of care (SoC)
Statistic ITT Set Safety set
FP (n = 40) SoC (n = 44) FP (n = 59) SoC (n = 45)
Total transected area (cm2) Median (range) 64 (3–225) 50 (10–200) 70 (3–316) 50 (10–200)
Area of TBS (cm2) Median (range) 4.0 (0.3–81.0) 4.0 (0.1–49.0) 7.1 (0.2–81.0) 4.0 (0.1–49.0)
Source of bleeding
Arterial Number 2 2 3 2
Venous Number 20 24 36 24
Mixed Number 18 18 20 19
ITT, intention to treat.
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Finally, two subjects had the FP placed and haemostasis was
achieved but not assessed until 4 min 30 s and 4 min 31 s after
randomization. Both were considered treatment failures for
primary efficacy.
In the ITT analysis, the absolute time to haemostasis was 4 min
(range 4 to 13.2 min) compared with 9.7 min (range 4 to
31.3 min) in the SoC group (P < 0.001). Similar results were
obtained in the safety group analysis [4 min (range 4 to 13.2 min)
versus 9.7 min (range 4 to 31.3 min) P < 0.001].
Blood loss and transfusion requirements
The volume of blood lost during surgery was estimated by
the investigator taking into account measured losses in suction
and surgical swabs. The median estimated blood loss was
300 ml (range 20–2800 ml) in the FP group and 400 ml
(range 50–3000 ml) in the SoC group (P = 0.491). Similar figures
were estimated in the safety set. In the ITT analysis, 12/40
(30%) patients in the FP group and 18/44 (40.9%) in the
SoC group required a red cell transfusion in the period
between the commencement of surgery and the day-30 assess-
ment (P = 0.42).
Post-operative course
There was no difference in the post-operative intensive care unit
stay for patients treated with the FP or SoC (67.7 h  52.3 h
versus 36.5 h 25.4 h) or in total hospital stay (9.4 4.4 nights in
FP group versus 10.9 6.3 nights in the SoC group). No patient
died within 60 days of surgery and there were no deaths in either
treatment group during the study.
Post-operative drains and bile leak
Bile leaks occurred in 5/59 (8.5%) of patients treated with FP and
5/45 patients treated with SoC (11.1%) in the safety set (P <
0.059). A radiologically guided percutaneously placed drain was
used to treat one of five patients in the FP group and two of five
patients in the SoC group. No action was required in the other
patients. Post-operative fluid collections at the liver bed were
present in 2/59 (3.4%) of the FP group and 6/45 (13.3%) in the
SoC group (P < 0.059).
Adverse events and safety
A total of 462 adverse events occurred in patients treated with the
FP, with 56/59 (94.9%) experiencing at least one event of which 23
of the events were categorized as serious. In comparison there were
449 adverse events documented in 43 of 45 patients treated with
SoC, and thirteen were classified as serious. The adverse events
occurring in both treatment groups are summarized in Table 6.
Table 5 Haemostatic success at 4 and 10 min from randomization [intention-to-treat (ITT) set]
Hepatic parenchyma Fibrin pad Standard of care P-value Treatment difference
Haemostasis at 4 min
All 33/40 13/44 <0.001 53.0%
Normal 23/28 11/33 0.001 48.8%
Abnormal 10/12 2/11 0.001 65.2%
Haemostasis at 10 min
All 38/40 30/44 0.018 25.2%
Normal 27/28 23/33 NS 24.5%
Abnormal 11/12 7/11 NS 28.1%
NS, non-significant.
Table 6 Adverse events occurring in  10% of patients treated with
either the fibrin pad (FP) or standard of care (SoC)
System Adverse event Number (%) patients
experiencing an event
FP (n = 59) SoC (n = 45)
General Peripheral oedema 4 9
Pain 15 18
Pyrexia 15 12
Haemopoietic Anaemia 14 11
Cardiac Tachycardia 6 5
Gastrointestinal Constipation 22 20
Intra-abdomina
l collection
2 6
Nausea 31 28
Vomiting 20 14
Metabolic Hyperglycaemia 1 5
Hypokalaemia 14 11
Hypomagnesemia 9 3
Musculoskeletal Arthralgia 8 7
Nervous Dizziness 9 7
Anxiety 8 3
Confusional state 3 5
Hallucination 3 5
Insomnia 9 7
Renal Incontinence 0 5
Respiratory Pleural effusion 7 8
Vascular Hypertension 6 10
Hypotension 21 17
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Adverse events that were considered to be possibly or probably
related to study treatment occurred in 3/59 (5.1%) in the FP
group and no patients in the SoC group. The three adverse events
with a possible relationship to treatment with the FP were an
intra-abdominal collection after a hepatectomy. This was diag-
nosed with an abdominal CT scan on post-operative day 5 and
treated with insertion of a drain. In a second patient, a total of
1480 ml of serosanguinous fluid was drained into a surgical drain
within 24 h of liver resection. This was treated with a transfusion
and resolved without operative intervention. Finally, a third
patient lost 2000 ml of blood into a surgical drain in the first 48 h
after a hepatectomy. This was managed with transfusion and cor-
rection of underlying coagulation anomalies and settled within
48 h without requiring re-operation. In these latter two patients
there was no reoperation or further imaging studies to confirm
TBS rebleeding. Within the SoC group, no causal relationship to
any adverse event could be established as this was a standard
surgical technique to achieve haemostasis rather than an investi-
gational product.
All adverse events were assessed for any potential relationship to
rebleeding at the TBS. One case of an intra-operative haemor-
rhage and one case of a post-operative haemorrhage were assessed
as being potentially related to rebleeding at the TBS.
In the safety set, 2/45 (4%) patients treated with SoC developed
thrombotic complications (vena caval thrombosis after a caval
resection and portal vein thrombosis) and 1/59 (2%) patients
treated with the FP developed a proven pulmonary embolism. No
other thromboembolic events were documented.
Discussion
This was a randomized, controlled superiority study to evaluate
the effectiveness of the FP compared with SoC utilized to control
bleeding in hepatic parenchyma, after a hepatectomy, for which
standard methods of achieving haemostasis were ineffective,
impractical or inappropriate. The trial was randomized to avoid
treatment bias and to ensure that the patient groups were compa-
rable. Stratification for the type of hepatic parenchyma was
undertaken to ensure a balanced distribution of patients with
normal and abnormal parenchyma across the treatment groups
and to enable some conclusions to be drawn regarding the efficacy
of the FP in a variety of conditions. Formal training of participat-
ing surgeons was also required to ensure that the FP was correctly
applied, the definition of TBS uniformly applied and the conduct
of the trial was standardized – particularly the timing between
randomization, pad application and assessment of haemostasis at
4 and 10 min. In addition, a ‘run in’ phase was also included so
that the first two patients randomized in the operating room were
treated with the FP to further embed the procedures necessary for
the correct conduct of the trial. The control arm of the trial was
manual compression with either a gauze swab plus or minus oxi-
dized regenerative cellulose. This was chosen as these are widely
available products, have been used as comparison in previous
trials of the FP and constituted a reasonable and acceptable inter-
national standard of care. Finally, careful consideration was given
during the trial design to a blinded design with a placebo pad as
the control group. This would have required manufacture of a
placebo pad with the same controls as the FP which was not
feasible and, as the FP is made up of three separate products,
would have lead to a trial with at least two experimental arms.
The accurate definition of the TBS was crucial in standardizing
the trial conditions across the various centres and was carefully
developed to enable other trials of regional haemostatic products
to be undertaken in the future using a reproducible format. The
TBS was defined as the first actively bleeding site identified in the
hepatic parenchyma after transection. The TBS also had to be
non-responsive to 30 s of manual compression and require the
surgeon’s immediate attention. These two criteria were set to
define a significant bleeding point, rather than minor surface
ooze, that if left untreated would have significant haemodynamic
consequences for the patient. The time of 30 s manual compres-
sion was deliberately chosen to reflect the common practice of
surgeons to treat minor bleeding with short periods of compres-
sion and to eliminate the randomization of patients with clinically
insignificant bleeding. In addition, conventional methods of
control (suture, ligature, cautery and argon beam coagulation)
were deemed to be ineffective, impractical or inappropriate. This
final criterion effectively excluded minor blood loss that could be
addressed with cautery or argon beam and discrete open vessels
that should be appropriately dealt with by suture or ligature.
Finally the TBS had to be a site where occlusion of the injured
surface vessels was required to achieve haemostasis. This specifi-
cally excluded large defects in arteries or veins where the wall
required repair with maintenance of vessel patency. Persistent
exposure of the FP to blood flow and pressure during healing and
absorption is contraindicated because of the possibility of later
arterial pseudoaneurysm and the theoretical possibility of wide-
spread intravascular activation of the coagulation cascade.
This investigation has demonstrated that the FP is superior to
SoC in achieving parenchymal haemostasis after a hepatectomy.
The FP achieved haemostasis in 82.5% of patients in comparison
to SoC which was effective in achieving haemostasis in 29.5% of
patients. This was a highly significant difference and resulted in
the trial being stopped at the first interim analysis. In addition, the
effectiveness of the FP was maintained in patients with abnormal
hepatic parenchyma (90.9% patients versus 18.2% patients in the
SoC group). This is an important finding as steatotic or cirrhotic
parenchyma is technically more demanding to operate on and
often blood loss is higher in these procedures. This is related to the
increased fragility of the parenchyma, associated hepatic dysfunc-
tion and the technical difficulty of using sutures and other
methods of coagulation on friable, fragile tissue. As hepatic resec-
tion is increasingly utilized to treat patients with primary and
secondary hepatic malignancy, many patients are presenting for
treatment with well-compensated cirrhosis or steatosis after pre-
operative chemotherapy4,16 and the development of techniques to
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undertake surgery in these patient groups is an area of focus for
hepatobiliary surgeons. This trial has demonstrated that the FP
will positively contribute to the management of these patients and
provides further evidence that fibrin-based products have a sig-
nificant role to play in the management of bleeding after a hepa-
tectomy.17 Finally, the high concentrations of fibrin and thrombin
delivered to the site of bleeding by the FP indicate that it will
remain effective in patients with depletion of endogenous clotting
factors.
In this trial, while the patients treated with FP clearly achieved
haemostasis before those treated with SoC, operative time, inten-
sive care stay and overall hospital stay were similar. In addition,
while the measured blood loss and transfusion requirements were
lower in the FP-treated cases these did not reach statistical signifi-
cance. However, the primary endpoint of this trial was the time
taken to achieve inta-operative haemostasis and the statistical
analysis and power calculations were undertaken with this aim.
Transfusion requirement and hospital stays were secondary end-
points. The strong trends shown in the data suggest that an
adequately powered study, with these as primary endpoints, uti-
lizing the FP would achieve a positive result.
The effectiveness of the FP in achieving haemostasis is related
to its mode of action. Activation of the fibrinogen and thrombin
on the biological surface results in local clot formation. Signifi-
cantly the surface does not need to be dry but the pad must be
applied closely to the surface, even if it is irregular. This results in
adherence of the FP to the tissue forming a tight and adhesive
seal. Failure of the FP can occur if it is moved before the adher-
ence occurs or if the FP does not conform to the tissue. This is a
particular risk in the liver if the FP is incorrectly applied to focal
parenchymal defects so that they are bridged rather than covered.
This can result in ongoing bleeding in the defect and eventual
lifting of the FP. In this study, there were seven treatment failures
in patients treated with the FP. Two patients achieved haemosta-
sis but this was not assessed at 4 min and they were counted as
treatment failures and one patient was wrongly randomized to
SoC but was counted as a FP failure. In one patient with a cylin-
drical defect after a metastatectomy the FP did not conform
exactly to the tissue defect so had to be replaced, and in one
patient an arterial bleed which should have been treated with
suture ligation bled through the FP. Of the remaining two
patients, hemostasis was achieved at 4 min but the pad was
manually dislodged at 9 min with hemostasis re-established
using another FP and in the final patient seepage at the edge of
the FP continued at 4 min but was absent at 10 min following
further manual compression. While these patients were correctly
analysed as treatment failures it is important to note that there
was no instance of the FP not functioning, when correctly
applied.
A further observation in the trial was the effect the FP had on
the frequency of post-operative bile leaks and collections at the
surgical site. Overall, the presence of post-operative intra-
abdominal collections was less frequent in the FP-treated patients
(3.4% versus 13.3% in the SoC patients) and the incidence of
post-operative bile leaks was 5/59 (8.5%) in the FP group versus
5/45 (11.1%) in the SoC group. For both intra-abdominal collec-
tions and bile leaks the level of significance was marginally greater
than 0.05. Other investigators have demonstrated the importance
of adherence strength of fibrin-based products at maintaining clot
integrity at the liver edge18 and also the potential role this effect
has in sealing the liver edge and reducing the risk of post-resection
bile leak and intra-abdominal collection.19
One of the potential attractions of the FP is its safety profile. It
is a composite of oxidized, regenerative cellulose and polyglactin
fibres. Both of these materials have been in clinical use for several
decades and are fully absorbed under physiological conditions.
Human fibrinogen and thrombin are bound to the polyglactin
fibres in high concentrations. The fibrinogen and thrombin was
obtained from pooled plasma and is treated for known infective
agents. This treatment involves screening for all known viral
markers followed by solvent detergent treatment for inactivation
of lipid enveloped virus. The plasma is then pasteurized and nano-
filtered for non-specific virus inactivation and removal. As part of
this trial, patients treated with FP had blood banked, with their
consent, for 5 years after randomization to enable any retrospec-
tive testing for viral or other infections should this become nec-
essary in the future.
In the development of this trial, infected collections at the
operative site and thromboembolic disease were recognized as
potential complications of FP application. However, only three
patients treated with FP were considered to have had an adverse
event potentially related to the FP. One of these was an intra-
abdominal collection managed with drainage, and two patients
had post-operative drain losses managed conservatively. Only
two patients in the SoC group and one patient in the FP group
developed thromboembolic complications. All patients had a
high-risk score pre-operation for thromboembolic disease indi-
cating that the patient population overall was a high risk one.
However, this study and two other trials utilizing the FP in mod-
erate and severe soft tissue bleeding have not confirmed any
increased risk of thromboembolic events in patients treated with
the FP.
This investigation has confirmed that the FP is safe and effec-
tive at treating parenchymal bleeding after an elective hepatec-
tomy in a variety of parenchymal types. It has also been shown
to be effective in managing soft tissue bleeding in a variety of
soft tissue sites particularly tumour beds after resection, the
pelvis after resection of the rectum and the urinary bladder, the
renal bed after nephrectomy and in the mediastinum and tho-
racic cavity. The FP is straightforward to store and use and does
not require complex preparation. It has not yet been assessed in
the acute setting but the possibilities for its application in
trauma surgery, damage control surgery and even as a field
dressing are obvious. While the FP will never be a substitute for
accurate and careful surgical technique it represents a significant
advance in the field of regional haemostasis and it provides
HPB 69
HPB 2013, 15, 61–70 © 2012 International Hepato-Pancreato-Biliary Association
surgeons with a significant addition to their intra-operative
armamentarium.
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